Ukena D, Hellwig D
Medizinische Universitätsklinik, Innere Medizin V, Universitätsklinikum des Saarlandes, D-66421 Homburg, Germany.
Lung Cancer. 2004 Aug;45 Suppl 2:S75-8. doi: 10.1016/j.lungcan.2004.07.989.
Metabolic imaging with positron emission tomography (PET) using 18F-fluoro-2-deoxy-glucose (FDG) has been accepted as an important imaging modality in lung cancer. FDG PET may have important impacts on the management of lung-cancer patients, for instance by improvement of locoregional (mediastinal) and extrathoracic staging (unexpected metastases). Interesting findings have now been reported in the response assessment to induction therapy providing results of greater prognostic significance than that obtained by conventional imaging methods. In the field of thoracic irradiation, FDG PET may provide advantages in terms of reduced toxicity, treatment intensification, better local tumour control and increased survival.
使用18F-氟-2-脱氧葡萄糖(FDG)的正电子发射断层扫描(PET)代谢成像已被公认为肺癌的一种重要成像方式。FDG PET可能对肺癌患者的治疗管理产生重要影响,例如通过改善局部区域(纵隔)和胸外分期(意外转移)。目前在诱导治疗的反应评估中已报道了一些有趣的发现,其提供的结果比传统成像方法具有更大的预后意义。在胸部放疗领域,FDG PET在降低毒性、强化治疗、更好地控制局部肿瘤和提高生存率方面可能具有优势。